Celltrion to launch HIV treatment Temixys

Celltrion is set to launch its latest product in the coming weeks, the company announced Monday. Temixys, which the Food and Drug Administration approved last November, is indicated as a single-tablet regimen to treat HIV in combination with other antiretroviral agents. 

Temixys combines lamivudine and tenofovir disoproxil fumarate (300 mg each). The company noted that it plans to supply the drug at a significantly discounted wholesale acquisition cost among tenofovir-based combination products. The Korean drugmaker’s U.S. headquarters in New Jersey will focus on direct distribution and promoting market access to expand HIV treatment options and accessibility for patients. 

As part of the launch, besides education events for prescribers, Celltrion has launched the TuneUpTogether mobile app, meant to help HIV-positive patients and medical personnel better understand Temixys. The app is available in both the Google Play Store and Apple App Store.